Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(14):1037; doi:10.1093/jnci/95.14.1037
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 14, 1037, July 16, 2003
© 2003 Oxford University Press

NEWS

In Brief

The first 10% of the full text of this article appears below.

AstraZeneca Pleads Guilty to Criminal Conspiracy

Pharmaceutical company AstraZeneca pleaded guilty to criminal conspiracy after a government investigation revealed pricing and marketing practices of the prostate cancer drug Zoladex (goserelin) that violated the Prescription Drug Marketing Act.

The company admitted that they provided free samples of Zoladex to physicians with the understanding that the physicians would charge their patients and insurance programs for the drug. This practice resulted in an estimated loss of $40 million, for which AstraZeneca has agreed to pay a $63 million criminal fine.

The . . . [Full Text of this Article]

Paclitaxel Combination Improves Survival From Relapsed Ovarian Cancer

Studies Detail Risk of Breast Cancer with HRT

Regular Aspirin Use Associated with Reduced Risk of Leukemia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?